You are viewing: Rest Of Europe Oral Proteins & Peptides Market analysis

The Rest Of Europe Oral Proteins & Peptides Market was valued at $104.8 Million in 2025 and projected to reach to $244.4 Million by 2030, representing a compound annual growth rate of 18.4%. Rest Of Europe's oral proteins & peptides market is positioned for sustained growth driven by increasing prevalence of chronic diseases, rising healthcare expenditures, and growing patient preference for non-invasive oral delivery systems.

Rest Of Europe Oral Proteins & Peptides Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Rest Of Europe Oral Proteins & Peptides Market Trends and Insights

  • This 18.4% compound annual growth rate reflects strong demand across Rest Of Europe for innovative oral delivery solutions that improve bioavailability and patient compliance.
  • Rest Of Europe is capitalizing on advances in formulation technology and increasing adoption of peptide-based therapeutics across multiple therapeutic areas. The market in Rest Of Europe is driven by rising prevalence of chronic diseases, aging populations, and growing investment in biotechnology infrastructure.
  • Rest Of Europe's regulatory environment continues to support novel oral formulations, enabling faster market entry for innovative products.
  • Key players in Rest Of Europe are focusing on strategic partnerships and R&D investments to strengthen their competitive positions and expand their product portfolios throughout the forecast period..

Key Market Statistics

  • CAGR (2025-2030) 18.4% CAGR
  • Market Size, 2025 ~USD 104.8 Million
  • Forecast, 2030 ~USD 244.4 Million
  • Country Rest Of Europe

Rest Of Europe Oral Proteins & Peptides Market Overview

Strong Regional Growth Trajectory :

Rest Of Europe's oral proteins & peptides market is expanding at 18.4% CAGR, demonstrating robust investor confidence and sustained demand for advanced oral delivery technologies across the region's diverse healthcare markets.

Significant Market Expansion :

Market valuation is projected to more than double from USD 104.8 million in 2025 to USD 244.4 million by 2030, reflecting accelerating adoption of oral protein therapeutics and peptide-based treatments across Rest Of Europe.

Bioavailability Innovation Focus :

Rest Of Europe is witnessing increased investment in formulation technologies that enhance oral bioavailability, addressing key barriers to peptide and protein drug delivery while improving patient compliance and treatment outcomes.

Regulatory Support & Market Access :

Favorable regulatory frameworks across Rest Of Europe countries are facilitating faster market entry for innovative oral protein and peptide therapeutics, creating competitive advantages for early-stage companies and established pharmaceutical players.

Rest Of Europe Oral Proteins & Peptides Market Dynamics

  • The region's pharmaceutical sector is actively investing in advanced formulation technologies to overcome bioavailability challenges inherent to protein and peptide therapeutics. Key growth drivers include expanding geriatric populations requiring chronic disease management, strengthening healthcare infrastructure across emerging European markets, and collaborative partnerships between biotech firms and academic institutions.
  • The market's 18.4% CAGR reflects confidence in oral delivery innovations that enhance therapeutic efficacy while reducing treatment burden, positioning Rest Of Europe as a critical growth hub within the broader European pharmaceutical landscape..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • SANOFI
  • Pfizer Inc.
  • NOVARTIS

    Key Takeaways

    • Rest Of Europe's oral proteins & peptides market will more than double from USD 104.8M (2025) to USD 244.4M (2030), representing an 18.4% CAGR.
    • Rest Of Europe demonstrates strong adoption of oral peptide therapeutics driven by technological innovation and supportive regulatory frameworks.
    • Rest Of Europe's aging demographic and rising chronic disease burden are key catalysts accelerating market growth through 2030.
    • Rest Of Europe's competitive landscape is intensifying as companies pursue partnerships and R&D investments to capture emerging opportunities.

    Oral Proteins & Peptides Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment OBESITY & OVERWEIGHT (Therapeutic Area)
    Forecast Period 2025–2030
    Growth Rate CAGR of 22.1% from 2025 to 2030
    Largest Segment TABLETS (Formulation)
    Market Size Base Year (Billions) ~USD 8.84 (2025)
    Revenue Forecast (Billions) ~USD 24 (2030)
    Segments Covered Molecule, Drug Class, Formulation, Therapeutic Area, End User

    Rest Of Europe Oral Proteins & Peptides Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Molecule

    • Calcitonin
    • Linaclotide
    • Other Molecules
    • Plecanatide
    • Semaglutide
    • Trofinetide
    • Voclosporin

    By Drug Class

    • Cgrp Receptor Antagonists
    • Cnis
    • Gc-C Agonists
    • Glp-1 Receptor Agonists
    • Gpe
    • Other Drug Classes

    By Formulation

    • Capsules
    • Oral Solutions
    • Tablets

    By Therapeutic Area

    • Cns Disorders
    • Diabetes
    • Gastroenterology
    • Genetic Disorders
    • Nephrology
    • Obesity & Overweight
    • Other Therapeutic Areas

    By End User

    • Home Care Settings
    • Hospitals & Specialty Clinics
    • Long-Term Care Facilities

    Target Audience

    • Pharmaceutical & Biotech Companies : Manufacturers and developers of oral protein and peptide therapeutics require Rest Of Europe-specific market data to guide R&D investments, commercialization strategies, and regional expansion planning within this high-growth segment.
    • Healthcare Investment Firms : Private equity, venture capital, and strategic investors need detailed Rest Of Europe market analysis to identify promising portfolio companies, assess regional growth potential, and evaluate acquisition targets in oral delivery technologies.
    • Contract Manufacturing Organizations (CMOs) : CMOs and contract development partners require Rest Of Europe market intelligence to anticipate manufacturing demand, plan capacity expansion, and develop specialized formulation capabilities for regional pharmaceutical clients.
    • Healthcare Policy & Regulatory Bodies : Government agencies, health ministries, and regulatory authorities in Rest Of Europe need market insights to inform reimbursement policies, regulatory frameworks, and healthcare innovation strategies for oral protein therapeutics.
    • Market Research & Consulting Firms : Research organizations and management consultants require granular Rest Of Europe market data to support client advisory services, competitive benchmarking, and strategic planning across the oral proteins & peptides sector.

    Key Companies in the Rest Of Europe Oral Proteins & Peptides Market

    CompanyHQOwnershipStrongest segments
    NOVO NORDISK A/SDenmarkPublic CompanyObesity and Diabetes Care – GLP-1 injectables (including Wegovy),Obesity and Diabetes Care – oral GLP-1 and other diabetes therapies,Rare Disease – rare blood and endocrine disorders,
    ABBVIE INC.United StatesPublic CompanyImmunology (Skyrizi, Rinvoq and related autoimmune/inflammatory),Oncology/Hematology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis),Neuroscience & CNS (Vraylar, Duodopa, Vyalev and related),
    PFIZER INC.IndiaPublic CompanyInternal medicine (CV, respiratory, gastro, multivitamins, neuroscience, women’s health),Vaccines,Injectables and anti-infectives,
    BAUSCH HEALTH COMPANIES INC.CanadaPublic CompanyBausch + Lomb (eye health),Salix (gastroenterology and hepatology),Solta Medical (aesthetic medical devices),
    ACADIA PHARMACEUTICALS INC.United StatesPublic CompanyNUPLAZID (Parkinson’s disease psychosis),DAYBUE / trofinetide (Rett syndrome),Pipeline and other revenues,
    AURINIA PHARMACEUTICALS INC.CanadaPublic CompanyLUPKYNIS (voclosporin) for lupus nephritis,Other pipeline and collaboration revenue (including aritinercept-related),
    MERCK & CO., INC.United StatesPublic CompanyOncology (Keytruda, Keytruda Qlex, Welireg, ADC collaborations, Lynparza co-commercialization),Vaccines (Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23),Hospital & Specialty (Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/Verquvo, Ohtuvayre),
    SWK HOLDINGSUnited StatesPrivate Investment FirmHealthcare venture debt (biopharma, medtech, diagnostics, life science tools),Healthcare services and HIT lending,Technology and SaaS venture debt (non-healthcare),
    ENTERA BIO LTD.IsraelPublic CompanyEB613 – oral teriparatide (osteoporosis, stress fractures),EB612 – hypoparathyroidism peptide replacement,EB618 – GLP-1/glucagon dual agonist (obesity, metabolic, fibrotic),
    ASTRAZENECA PLCUnited KingdomPublic CompanyOncology (Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Imjudo, others),Cardiovascular, Renal & Metabolism (Farxiga/Forxiga, Brilinta/Brilique, Crestor, diabetes combinations),Respiratory & Immunology (Symbicort, Fasenra, Tezspire, Breztri, Airsupra, others),

    NOVO NORDISK A/S

    Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 with 67,900 employees. Operating as a public company, it is a major player in the global pharmaceutical industry.

    ABBVIE INC.

    AbbVie Inc. is a United States-based public pharmaceutical company established in 2012 with 57,000 employees. The company operates in the pharmaceutical sector with significant global operations.

    PFIZER INC.

    Pfizer Inc. operates as a public company in India with 1,244 employees, having been established in 1950. The company is engaged in pharmaceutical operations in the Indian market.

    BAUSCH HEALTH COMPANIES INC.

    Bausch Health Companies Inc. is a Canadian public company with 20,300 employees operating in the pharmaceutical and healthcare sectors.

    ACADIA PHARMACEUTICALS INC.

    Acadia Pharmaceuticals Inc. is a United States-based public pharmaceutical company founded in 1993 with 797 employees. The company focuses on pharmaceutical development and commercialization.

    AURINIA PHARMACEUTICALS INC.

    Aurinia Pharmaceuticals Inc. is a Canadian public company established in 1993 with 128 employees. The company operates in the pharmaceutical sector.

    MERCK & CO., INC.

    Merck & Co., Inc. is a United States-based public pharmaceutical company founded in 1891 with 74,000 employees. It is one of the world's largest pharmaceutical manufacturers.

    SWK HOLDINGS

    SWK Holdings is a United States-based private investment firm founded in 1996 with 9 employees.

    ENTERA BIO LTD.

    Entera Bio Ltd. is an Israeli public company founded in 2009 with 21 employees operating in the pharmaceutical sector.

    ASTRAZENECA PLC

    AstraZeneca PLC is a United Kingdom-based public pharmaceutical company founded in 1992 with 96,100 employees. It is a major global pharmaceutical manufacturer.

    Reasons to Buy this Report

    • Regional Market Sizing & Forecasting : Obtain precise market valuations specific to Rest Of Europe (USD 104.8M in 2025, USD 244.4M in 2030) with detailed 5-year projections, enabling accurate budget allocation and investment planning tailored to regional growth dynamics.
    • Competitive Landscape Intelligence : Gain insights into Rest Of Europe's competitive positioning, key market players, and differentiation strategies within the oral proteins & peptides segment, supporting strategic market entry and competitive positioning decisions.
    • Growth Driver Analysis : Understand region-specific factors driving the 18.4% CAGR in Rest Of Europe, including regulatory environment, healthcare infrastructure, patient demographics, and technological adoption patterns unique to the region.
    • Investment & Partnership Opportunities : Identify high-potential investment targets, acquisition candidates, and strategic partnership opportunities within Rest Of Europe's expanding oral protein and peptide therapeutics ecosystem.
    • Regulatory & Market Access Pathways : Access detailed information on Rest Of Europe's regulatory frameworks, reimbursement landscapes, and market access strategies specific to oral protein and peptide products across different country markets.

    Frequently asked questions

    What is the current market size of oral proteins & peptides in Rest Of Europe?

    Rest Of Europe's oral proteins & peptides market was valued at USD 104.8 million in 2025 and is expected to grow significantly through the forecast period.

    What is the projected market size for Rest Of Europe by 2030?

    Rest Of Europe's oral proteins & peptides market is forecasted to reach USD 244.4 million by 2030, representing more than a doubling of market value.

    What is the CAGR for Rest Of Europe's oral proteins & peptides market?

    Rest Of Europe's oral proteins & peptides market is projected to grow at a compound annual growth rate of 18.4% from 2025 to 2030.

    What factors are driving growth in Rest Of Europe's oral proteins & peptides market?

    Rest Of Europe's market growth is driven by aging populations, rising chronic disease prevalence, technological advances in oral delivery, and supportive regulatory environments.

    How is Rest Of Europe positioned compared to other European markets?

    Rest Of Europe represents a significant portion of the European oral proteins & peptides market, with strong growth momentum supported by regional healthcare investments and innovation ecosystems.

    RESEARCH METHODOLOGY

    This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global oral proteins and peptides market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

    Secondary Research

    Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the oral proteins and peptides market. The secondary sources used for this study include the World Health Organization (WHO), National Institutes of Health (NIH), United States Food and Drug Administration (US FDA), European Medicines Agency (EMA), National Center for Biotechnology Information (NCBI), BioPharm International, International Diabetes Federation, ScienceDirect, ClinicalTrials.gov, PubMed, European Federation of Pharmaceutical Industries and Associations (EFPIA), European Lead Factory (ELF), India Brand Equity Foundation (IBEF), UK Research Partnership Investment Fund (UKRPIF), Pharmaceutical Research and Manufacturers of America (PhRMA), Eurostat, and Factiva; research journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; and trade, business, professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    Extensive primary research was conducted after acquiring basic knowledge about the global oral proteins and peptides market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biotechnology companies, CROs, CMOs, and academic & research institutes, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

    The following is a breakdown of the primary respondents:

    Oral Proteins and Peptides Market

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The bottom-up approach was used to estimate and validate the total size of the oral proteins and peptides market. These methods were also extensively utilized to estimate the size of various subsegments within the market. The research methodology used to estimate the market size includes the following:

    • The list of approved oral proteins and peptides was identified through extensive secondary and primary research.
    • The oral protein and peptide products in the pipeline were identified from clinical trial registries and from secondary and primary research related to peptide and protein therapeutics.
    • The revenues generated from these oral proteins and peptides were determined through annual reports and secondary sources (including paid databases).
    • The products were categorized according to market segments. Percentage shares and splits were calculated based on revenue contributions for each segment. This information was validated using secondary sources and insights from industry experts.
    • All assumptions, approaches, and individual shares/revenue estimates were validated through expert interviews.

    Global Oral Proteins and Peptides Market Size: Bottom-up Approach

    Oral Proteins and Peptides Market

    Data Triangulation

    After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

    Market Definition

    Oral proteins and peptides are therapeutic drugs made from proteins or peptides (short chains of amino acids) that are meant to be taken by mouth. These biologically active molecules are designed to treat a variety of medical conditions, including chronic diseases such as diabetes, hormonal disorders, and autoimmune disorders.

    Stakeholders

    • Pharmaceutical & biotechnology companies
    • Hospitals
    • Specialty clinics
    • Long-term care facilities
    • Patient advocacy organizations
    • Academic researchers and government research organizations
    • Private research institutes
    • Contract manufacturing organizations (CMOs)
    • Contract research organizations (CROs)
    • Venture capitalists

    Report Objectives

    • To define, describe, and forecast the oral proteins and peptides market based on molecule, drug class, therapeutic area, formulation, end user, and region
    • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall oral proteins and peptides market
    • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six main regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To profile the key players in the oral proteins and peptides market and comprehensively analyze their product portfolios, market positions, and core competencies
    • To track and analyze competitive developments in the oral proteins and peptides market, such as acquisitions, product launches/approvals, expansions, agreements, partnerships, and collaborations
    • To benchmark players within the oral proteins and peptides market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business strategy and product strategy

     

    Get the Full Oral Proteins & Peptides Market Report

    Full forecast, segment splits, and company analysis for all Oral Proteins & Peptides Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status